PROLIFICA: a story of West African clinical and research collaborations to target hepatitis B-related hepatocellular carcinoma in West Africa
| Autor: | Simon D. Taylor-Robinson, Makie Taal, Nimzing G. Ladep, Shevanthi Nayagam, Edith N. Okeke, Mary M.E. Crossey, M. Mourtalla Ka, Maud Lemoine, Mark Thursz, Deborah A. Garside, Ramou Njie, Jessica Howell |
|---|---|
| Přispěvatelé: | Commission of the European Communities, Imperial College Healthcare NHS Trust- BRC Funding, Medical Research Council (MRC), Institut Merieux |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Biomedical Research Carcinoma Hepatocellular International Cooperation Population medicine.disease_cause 03 medical and health sciences Liver disease 0302 clinical medicine Environmental health General & Internal Medicine Research Support as Topic medicine Humans Longitudinal Studies Program Development education Hepatitis Hepatitis B virus education.field_of_study Transmission (medicine) business.industry Liver Neoplasms virus diseases General Medicine 11 Medical And Health Sciences Hepatitis B medicine.disease Virology digestive system diseases Europe Africa Western 030104 developmental biology 030220 oncology & carcinogenesis Hepatocellular carcinoma Case-Control Studies Commentary Liver cancer business Needs Assessment Program Evaluation |
| Popis: | Hepatitis B virus (HBV) infection is highly endemic in sub-Saharan Africa, where the lifetime risk of HBV infection is over 60% and more than 8% of the population remains chronic HBV carriers. Furthermore, this area has one of the highest HBV-related liver cancer rates in the world,1 being the most common cancer in men and third most common in women.2,3 HBV infection therefore represents a significant global threat to health in the African continent. Though most countries in sub-Saharan Africa have established HBV vaccination programs for infants through the WHO and Global Vaccine Alliance (GAVI)-sponsored Expanded Program of Immunization, HBV vaccine coverage remains incomplete.4 Furthermore, the current recommendation from World Health Organisation African division (WHO-AFRO) for birth dose HBV vaccination to prevent maternal-child transmission and early horizontal transmission of HBV has not been widely implemented.5 This is a critical issue in Africa, as more than 90% of children infected with HBV early in life progress to become chronic carriers of HBV, with the attendant risks of HBV-related liver disease, liver cancer and death.6,7 Severe limitations in healthcare infrastructure, availability of diagnostics and treatment mean that currently West Africa is ill-equipped to manage the exponentially increasing burden of disease relating to the HBV epidemic. Greater knowledge of the determinants of hepatocellular carcinoma (HCC) development and cost-effective point-of-care diagnostic tests for HBV-related liver disease, and HCC are significant unmet needs in West Africa. Since 1973, HBV research has been conducted … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|